Thorsten Vetter

1.1k total citations
13 papers, 321 citations indexed

About

Thorsten Vetter is a scholar working on Economics and Econometrics, Statistics and Probability and Immunology. According to data from OpenAlex, Thorsten Vetter has authored 13 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Economics and Econometrics, 5 papers in Statistics and Probability and 4 papers in Immunology. Recurrent topics in Thorsten Vetter's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Statistical Methods in Clinical Trials (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Thorsten Vetter is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Statistical Methods in Clinical Trials (5 papers) and Biosimilars and Bioanalytical Methods (4 papers). Thorsten Vetter collaborates with scholars based in Netherlands, Germany and Austria. Thorsten Vetter's co-authors include Martin J. Lohse, Jan Regnström, Robert Hemmings, Franz Koenig, Martin Posch, Spiros Vamvakas, Matthias P. Hofer, Falk Ehmann, Marisa Papaluca‐Amati and Amelie Elsäßer and has published in prestigious journals such as Nature Reviews Drug Discovery, Clinical Pharmacology & Therapeutics and Drug Discovery Today.

In The Last Decade

Thorsten Vetter

12 papers receiving 305 citations

Peers

Thorsten Vetter

NEPHR

IMMUN

Johanna Mielke Switzerland

Anna McGlothlin United States

Lee‐Jen Wei United States

Charles H. Hennekens United States

Boissel Jp France

Paul de Jong Netherlands

Christopher Tait United States

Zoraida Corte Spain

Pilar Fernández-Fernández Spain

Bernice Tsoi Canada

Johanna Mielke Switzerland

Thorsten Vetter

27 ×0.3

10 ×0.2

NEPHR

14 ×0.2

32 ×0.5

48 ×1.4

IMMUN

Citations per year, relative to Thorsten Vetter Thorsten Vetter (= 1×) peers Johanna Mielke

Countries citing papers authored by Thorsten Vetter

Since Specialization

Citations

This map shows the geographic impact of Thorsten Vetter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorsten Vetter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorsten Vetter more than expected).

Fields of papers citing papers by Thorsten Vetter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorsten Vetter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorsten Vetter. The network helps show where Thorsten Vetter may publish in the future.

Co-authorship network of co-authors of Thorsten Vetter

This figure shows the co-authorship network connecting the top 25 collaborators of Thorsten Vetter. A scholar is included among the top collaborators of Thorsten Vetter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thorsten Vetter. Thorsten Vetter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Zinserling, J., et al.. (2025). Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency. Clinical Pharmacology & Therapeutics. 117(5). 1226–1235. 1 indexed citations

Vetter, Thorsten, et al.. (2024). Identifying and overcoming challenges in the EMA’s qualification of novel methodologies: a two-year review. Frontiers in Pharmacology. 15. 1470908–1470908.

Vetter, Thorsten, Jan Regnström, Maria Tome, et al.. (2023). Patient‐reported, observer‐reported and performance outcomes in qualification procedures at the European Medicines Agency 2013–2018. British Journal of Clinical Pharmacology. 90(1). 299–312. 2 indexed citations

Vetter, Thorsten, et al.. (2023). EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age. Therapeutic Innovation & Regulatory Science. 57(4). 656–661. 5 indexed citations

Askin, Scott, Shibeshih Belachew, Timothy Kilchenmann, et al.. (2023). Evolving regulatory perspectives on digital health technologies for medicinal product development. npj Digital Medicine. 6(1). 56–56. 32 indexed citations

Vetter, Thorsten, et al.. (2022). Biomarkers in Medicines Development—From Discovery to Regulatory Qualification and Beyond. Frontiers in Medicine. 9. 878942–878942. 14 indexed citations

Bakker, Elisabeth, et al.. (2022). Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020. Clinical Pharmacology & Therapeutics. 112(1). 69–80. 30 indexed citations

Bakker, Elisabeth, Peter G. M. Mol, J.M. Valente Nabais, et al.. (2021). Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting. Frontiers in Pharmacology. 12. 662642–662642. 1 indexed citations

Vamvakas, Spiros, et al.. (2019). Multistakeholder Advice at the European Medicines Agency: Is It Still Needed?. Clinical Pharmacology & Therapeutics. 105(4). 819–821. 4 indexed citations

10.

Hofer, Matthias P., Maria Mavris, Franz Koenig, et al.. (2017). Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discovery Today. 23(2). 424–433. 24 indexed citations

11.

Hofer, Matthias P., Nikolaos Zafiropoulos, Spiros Vamvakas, et al.. (2015). Impact of scientific advice from the European Medicines Agency. Nature Reviews Drug Discovery. 14(5). 302–303. 38 indexed citations

12.

Elsäßer, Amelie, Jan Regnström, Thorsten Vetter, et al.. (2014). Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials. 15(1). 383–383. 55 indexed citations

13.

Vetter, Thorsten & Martin J. Lohse. (2002). Magnesium and the parathyroid. Current Opinion in Nephrology & Hypertension. 11(4). 403–410. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact